Presentations

• November 4, 2017
  

  Evaluating the Conceptual Equivalence Between Paper and Three Electronic Data Collection Modes of the EQ-5D-5L Health Status Instrument

  Crescioni M, Flood E, Lundy JJ, Coons SJ, Byrom B, Eremenco S. Evaluating the Conceptual Equivalence Between Paper and Three Electronic Data Collection Modes of the EQ-5D-5L Health Status Instrument. International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress; 2017 Nov 4; Glasgow, Scotland.

• November 1, 2017
  

  FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMRI) as a prognostic biomarker for pre-dementia clinical trials for Alzheimer disease therapeutics

  Conrado, D.J., et al.; “FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMRI) as a prognostic biomarker for pre-dementia clinical trials for Alzheimer disease therapeutics.” 10th Clinical Trials on Alzheimer’s Disease (CTAD), Boston, MA, November 1-4, 2017, The Journal of Prevention of Alzheimer’s Disease 4(4): 345.
• November 1, 2017
  

  Informed consent ensuring access to anonymized patient-level data and biospecimen is critical to accelerating innovative Alzheimer disease treatments

  Arnerić, S.P., et al.; “Informed consent ensuring access to anonymized patient-level data and biospecimen is critical to accelerating innovative Alzheimer disease treatments.” 10th Clinical Trials on Alzheimer’s Disease (CTAD), Boston, MA, November 1-4, 2017, The Journal of Prevention of Alzheimer’s Disease 4(4): 387.
• October 15, 2017
  

  Data sharing and standardization to expand a patient-level database of a regulatory-endorsed clinical trial simulator for Alzheimer disease (AD)

  Burton, J., et al.; “Data sharing and standardization to expand a patient-level database of a regulatory-endorsed clinical trial simulator for Alzheimer disease (AD).” The 8th American Conference on Pharmacometrics (ACoP8), Fort Lauderdale, FL, October 15-18, 2017.
• October 15, 2017
  

  Model-informed biomarker qualification: Alzheimer disease (AD) and Parkinson disease (PD) imaging biomarkers

  Conrado, D.J., et al.; “Model-informed biomarker qualification: Alzheimer disease (AD) and Parkinson disease (PD) imaging biomarkers.” The 8th American Conference on Pharmacometrics (ACoP8), Fort Lauderdale, FL, October 15-18, 2017.